Anti-Amyloid Antibody Formulation Stabilization
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for Alzheimer's disease, particularly those involving anti-Aβ antibodies, face challenges in effectively targeting and clearing amyloid plaques from the brain, leading to incomplete cognitive improvement and progression of the disease.
Innovation Solution
The development of pharmaceutical compositions comprising anti-Aβ antibodies, such as BIIB037, in combination with arginine hydrochloride, thiol-containing antioxidants, and excipients like polysorbate-80, which are formulated to stabilize the antibodies and enhance their ability to bind to and clear Aβ plaques, thereby slowing cognitive decline.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If anti-Aβ antibodies are administered to treat Alzheimer's disease, then Aβ plaque clearance is improved, but treatment efficacy is limited due to incomplete cognitive improvement
Solution Approach 1:
The patent modifies the chemical parameters of the antibody formulation by incorporating arginine hydrochloride and thiol-containing antioxidants, which change the stability and binding characteristics of the anti-Aβ antibody, thereby improving its therapeutic efficacy in clearing plaques and enhancing cognitive outcomes
Solution Approach 2:
The invention creates a composite pharmaceutical formulation combining anti-Aβ antibodies with arginine hydrochloride and thiol-containing antioxidants, where the synergistic interaction between these components enhances both plaque clearance and cognitive improvement beyond what the antibody alone achieves
2Reliability
If anti-Aβ antibody formulations are developed, then therapeutic potential is improved, but formulation stability challenges arise
Solution Approach 1:
The patent introduces arginine hydrochloride and thiol-containing antioxidants as intermediary substances that mediate between the anti-Aβ antibody and the formulation environment, protecting the antibody from degradation and maintaining its stability while preserving its therapeutic function
Solution Approach 2:
The formulation incorporates stabilizing agents (arginine hydrochloride and thiol-containing antioxidants) in advance to cushion against potential degradation of the anti-Aβ antibody during storage and administration, ensuring formulation stability before therapeutic action begins
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
These compositions demonstrate improved stability and efficacy in reducing Aβ burden in the brain, leading to slower cognitive deterioration and potential therapeutic benefits for Alzheimer's disease.
Implementation Method 1
BIIB037 binds with high apparent affinity to high molecular weight aggregates, presumably fibrils, of human Aβ. By immunohistochemistry, BIIB037 shows high affinity binding to Aβ plaques in human AD brain
Implementation Method 2
pharmaceutical compositions comprising anti-Aβ antibodies, such as BIIB037, in combination with arginine hydrochloride, thiol-containing antioxidants, and excipients like polysorbate-80, which are formulated to stabilize the antibodies
Implementation Method 3
thiol-containing antioxidants
Implementation Method 4
excipients like polysorbate-80
Data Source
AI summary
Pharmaceutical compositions containing anti-beta amyloid (Aβ) antibodies or Aβ-binding fragments thereof are provided. These pharmaceutical compositions find use in the treatment of abnormal accumulation or deposition of Aβ in the central nervous system, mild cognitive impairment, and Aβ-associated disorders such as Alzheimer's disease.